Search
Search results
50 results found
Publications
Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial
Julg, Boris, Kathryn E. Stephenson, Kshitig Wagh-, -Bette Korber, and Dan H. Barouch. 2022. “Safety and Antiviral Activity of Triple Combination Broadly Neutralizing Monoclonal Antibody Therapy Against HIV-1: A Phase 1 Clinical Trial”. Nature Medicine 28 (6): 1288-96.
Modeling resistance to the broadly neutralizing antibody PGT121 in people living with HIV-1
Cassidy, Tyler, Kathryn E. Stephenson, Dan H. Barouch, and Alan S. Perelson. 2024. “Modeling Resistance to the Broadly Neutralizing Antibody PGT121 in People Living With HIV-1”. PLoS Computation Biology 20.
Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study
Stieh, Daniel J., Dan H. Barouch, Christy Comeaux-, -Kathryn E. Stephenson-, -Hanneke Schuitemaker, and Frank Tomaka. 2023. “Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study”. Journal of Infectious Diseases 227 (8): 939-50.
Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination
Barouch, Dan H., Kathryn E. Stephenson, Jerald Sadoff-, -Johan van Hoof, and Hanneke Schuitemaker. 2021. “Durable Humoral and Cellular Immune Responses 8 Months After Ad26.COV2.S Vaccination”. New England Journal of Medicine 385 (10): 951-53.
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine
Sadoff, Jerald, Mathieu Le Gars, Georgi Shukarev-, -Kathryn E. Stephenson-, -Johan van Hoof, and Hanneke Schuitemaker. 2021. “Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine”. New England Journal of Medicine 384 (19): 1824-35.
MassCPR Symposium: Pandemic Preparedness (Video)
This annual symposium will convene both U.S. and global leaders to map a unified strategy for global pandemic preparedness. We will discuss how leading health organizations can come together to prepare for future outbreaks and what to do in the early stages of an outbreak to produce a coordinated...
Two mRNA-1273 Vaccine Doses Reduce Symptomatic COVID-19 in Younger Adults
Two mRNA-1273 vaccine doses reduced the incidence of COVID-19 infection in younger adults, though factors beyond vaccination may have contributed to infection risk.
Spotlight: Kathryn Stephenson on the Pandemic, Perseverance, and Women's History Month
This year's theme for Women's History Month is "Providing Healing, Promoting Hope." For Kathryn E. Stephenson, MD, MPH of Beth Israel Deaconess Medical Center's Center for Virology and Vaccine Research, it calls to mind the progress that has taken place since the beginning of the COVID-19 pandemic....